Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Colorcon
Merck
Farmers Insurance
Daiichi Sankyo
Argus Health
Mallinckrodt
AstraZeneca
Dow

Generated: July 18, 2018

DrugPatentWatch Database Preview

Regadenoson - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for regadenoson and what is the scope of regadenoson freedom to operate?

Regadenoson
is the generic ingredient in one branded drug marketed by Astellas and is included in one NDA. There are seventeen patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Regadenoson has eighty-five patent family members in twenty-six countries.

There are nine drug master file entries for regadenoson. One supplier is listed for this compound.
Summary for regadenoson
International Patents:85
US Patents:17
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 9
Suppliers / Packagers: 1
Bulk Api Vendors: 38
Clinical Trials: 52
Patent Applications: 82
DailyMed Link:regadenoson at DailyMed
Pharmacology for regadenoson
Synonyms for regadenoson
(1-(9-(3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6-aminopurin-2-yl)pyrazol-4-yl)-N-methylcarboxamide
(1-{9-[(4s,2r,3r,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-n-methylcarboxamide
1-(6-Amino-9-beta-D-ribofuranosyl-9H-purin-2-yl)-N-methyl-1H-pyrazole-4-carboxamide
1-[6-Amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-2-yl]-1H-pyrazole-4-carboxylic acid methylamide
1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-N-methylpyrazole-4-carboxamide
1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]purin-2-yl]-N-methyl-pyrazole-4-carboxamide
1-{6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-9H-purin-2-yl}-N-methyl-1H-pyrazole-4-carboxamide
2-[4-(methylcarbamoyl)-1h-pyrazol-1-yl]adenosine
2-[4-[(Methylamino)carbonyl]-1H-pyrazol-1-yl]adenosine
313348-27-5
348R275
6-Amino-2-[4-(methylcarbamoyl)-1H-pyrazol-1-yl]purine-9-yl-beta-D-ribofuranoside;1-(6-amino-9-((2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yloxy)-9H-purin-2-yl)-N-methyl-1H-pyrazole-4-carboxamide
7AXV542LZ4
AC1L55X1
AC1Q5LB1
Adenosine, 2-(4-((methylamino)carbonyl)-1H-pyrazol-1-yl)-
Adenosine, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]-
Adenosine,2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]-
AKOS026750593
AOB6869
API0000807
AT-36942
B5904
BDBM50119132
CAS-313348-27-5
CHEBI:135613
CHEMBL317052
CS-5612
CTK4G6871
CV-3146
CVT 3146
CVT-3146
CVT-3146;CVT3146;CVT 3146
D05711
D0XE1C
DB06213
DSSTox_CID_31501
DSSTox_GSID_57712
DSSTox_RID_97386
DTXSID4057712
FT-0674337
GTPL5596
HY-A0168
J-018384
Lexiscan
Lexiscan (TN)
LS-193008
LZPZPHGJDAGEJZ-AKAIJSEGSA-N
MolPort-006-170-140
NCGC00249892-01
NU001889
NU007666
Rapiscan
Regadenoson (USAN/INN)
Regadenoson [USAN:INN]
Regadenoson anhydrous
SCHEMBL678893
Tox21_113668
UNII-7AXV542LZ4
ZINC13818943

US Patents and Regulatory Information for regadenoson

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for regadenoson

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,278,435 N-pyrazole A2A receptor agonists ➤ Try a Free Trial
8,569,260 N-pyrazole A.sub.2A receptor agonists ➤ Try a Free Trial
8,071,566 Methods of coronary imaging ➤ Try a Free Trial
9,163,057 Methods of myocardial perfusion imaging ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for regadenoson

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2/2011 Austria ➤ Try a Free Trial PRODUCT NAME: REGADENOSON UND DESSEN SALZE
2011000010 Germany ➤ Try a Free Trial PRODUCT NAME: REGADENOSON UND DIE SALZE DAVON; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
785 Luxembourg ➤ Try a Free Trial 91785, EXPIRES: 20250621
2011 00005 Denmark ➤ Try a Free Trial PRODUCT NAME: REGADENOSON OG SALTE DERAF
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
QuintilesIMS
Teva
US Army
US Department of Justice
Citi
Johnson and Johnson
McKinsey
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.